cholesterol drugs top pharma for next 20 years ...bloomberg
CAPS is filing for IND in a few weeks.
Slides of fat plaques removed from arteries are impressive and available on line.
To prove my point, I am going to use the notes of a bullish analyst of Needham's Chad Messer. Messer likes the company's drug Juxtapid, which treats a rare cholesterol disease called Homozygous familial hypercholesterolemia (HoFH), and has led to Aegerion's 275% gains in 2013. Messer upgraded the stock, currently trading at $88, to $100 from $50. His logic is assuming that Juxtapid captures 17% of a targeted 14,000 patient population by 2018.
CAPS is just getting started treating Homozygous familial hypercholesterolemia with peptides. Ind to be filed 4q. Slides show outstanding results in removing plaques from arteries using peptides.
CAPS is at 26c right now, around where gale was 2 yrs ago.